Corn rootworms, pests responsible for billions of dollars in yearly crop losses, are evolving resistance that weakens even ...
That’s now happening. Researchers have uncovered genes that play a role in a number of chronic conditions. And they have invented new types of therapies to target their genetic roots. One of the most ...
According to DataM Intelligence, "The RNA-Based Therapies Market Size, valued at USD 90.56 billion in 2024, is projected to ...
GreenLight Biosciences ("the Company" or "GreenLight Bio") today announced the U.S. Environmental Protection Agency's (EPA) ...
Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 ...
(Reuters) -Swiss drugmaker Novartis has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its experimental candidates that target cardiovascular diseases, the ...
Ionis is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...
Ants rely on pheromones to coordinate their societies, but how do their neurons avoid sensory confusion? Researchers studying ...
(Reuters) -Swiss drugmaker Novartis has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its experimental candidates that target cardiovascular diseases, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback